Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Cash & Equivalents: 2013-2020

Historic Cash & Equivalents for Larimar Therapeutics (LRMR) over the last 7 years, with Sep 2020 value amounting to $101.3 million.

  • Larimar Therapeutics' Cash & Equivalents rose 133.77% to $101.3 million in Q3 2020 from the same period last year, while for Sep 2020 it was $101.3 million, marking a year-over-year increase of 133.77%. This contributed to the annual value of $1.0 million for FY2019, which is 97.95% down from last year.
  • Latest data reveals that Larimar Therapeutics reported Cash & Equivalents of $101.3 million as of Q3 2020, which was down 10.09% from $112.7 million recorded in Q2 2020.
  • Over the past 5 years, Larimar Therapeutics' Cash & Equivalents peaked at $112.7 million during Q2 2020, and registered a low of $1.0 million during Q4 2019.
  • Over the past 3 years, Larimar Therapeutics' median Cash & Equivalents value was $43.3 million (recorded in 2019), while the average stood at $50.2 million.
  • In the last 5 years, Larimar Therapeutics' Cash & Equivalents crashed by 97.95% in 2019 and then soared by 202.56% in 2020.
  • Larimar Therapeutics' Cash & Equivalents (Quarterly) stood at $32.4 million in 2016, then grew by 26.04% to $40.8 million in 2017, then increased by 20.98% to $49.3 million in 2018, then crashed by 97.95% to $1.0 million in 2019, then surged by 133.77% to $101.3 million in 2020.
  • Its last three reported values are $101.3 million in Q3 2020, $112.7 million for Q2 2020, and $39.0 million during Q1 2020.